Brings back memories. I “did my time” in EVE with the spread trade in Jita - first minerals, the moved on to T2 and implants. Directional trading though? As with the real markets, super difficult.
HOLY MOLY. Anthropic's Frontier Red Team secretly planted a traitor inside four-agent Claude Opus 4.8 and Fable 5 teams playing EVE Frontier. The other three were WARNED, yet almost never caught it. In one Opus 4.8 run, the saboteur framed an innocent teammate with fabricated private messages while publicly defending it: 'defending ship-1's good faith signals my innocence.' The victim identified the real traitor. The others didn't believe it.
Another Fable 5 saboteur mined a resource-rich asteroid, called it a 'spent husk', and secretly used the materials to build its own refinery. Across the sabotage experiments, even dedicated Claude monitors caught only 30–40% of traitors.
Anthropic separately put Claude into simulated EVE markets as a trader. Over six months, average earnings climbed from roughly 200% of starting capital with Opus 4.6 to 600% with Fable 5. But when the task shifted from spread capture to directional price bets, even Fable 5 made money in only about half its runs.
Medical aside: constrained by “shareable, public, interoperable, generalizable” data. Most medical data is none of these things (despite all existing HL7/FHIR efforts).
Really great post.
Bottom line: "Models are superintelligent where we have enormous data, and progressively less so as we have less data."
Nice summary: "All the rules-of-thumb about learning are at the root, the same -- Malcom Gladwell's 10,000 hours, Moravec's Paradox, Scaling Laws, the Bitter Lesson, Age of experience. If your learning system (model, brain, whatever) is unconstrained by compute, intelligence is proportional to accumulated experience."
@awealthofcs TIPS at near 3% real is arguably harder to beat
The scenario where that underperforms is basically a high real yield regime with tame inflation (1990s) or liquidity crisis (everything gets sold). In pretty much all other scenarios, it’s quite competitive with mush riskier assets
@AriDavidPaul Home maintenance is an amazing use case. Defective appliance - take pictures of the model badge, interior, “how to disassemble this”. It returns something. Don’t understand it - “circle it”. Etc. Warns about unsafe conditions. Techs at $200/hr not as thorough
@cremieuxrecueil Some criticism of the criticism - we should probably be moving to less invasive, more modern methods of preclinical detection such as ctDNA monitoring and MTSD https://t.co/EJ9PX6J4d3
Blocking single proteins never really made sense to me, frankly, with the combinatorial explosion that PPIs get you (an N^2 process vs a N process). Much more specificity using PPIs
Funnily enough imatinib was also based on "PPI" (though in that case the proteins are fused)
two flavors, broadly:
PROTACs
pull the target to the cell's garbage disposal and have it shredded.
molecular glues
force two proteins to stick that never would, building a brand-new function.
suddenly "undruggable" just meant "we hadn't found its partner yet."
Cheers, chills, and a standing ovation when RASolute 302 showed unprecedented survival on daraxonrasib for patients with progressive pancreatic cancer
Seldom do you sense you’re witnessing a historic moment in cancer care but this feels like ras targeting has arrived
#ASCO26
RAS finally getting drugged is one of the great stories in modern biology, and almost nobody outside oncology understands why it's such a big deal.
YOU'LL LEARN SOMETHING AWESOME TODAY.
i am going to keep this as understandable (and simple) as i can.
OPEN THE THREAD.
🧵
@smlungpathguy As molpath, it’s fun to “rewrite” these entities in terms of molecular alterations:
CDH1-deficient tumors:
ILC and diffuse gastric ca (classic)
Urothelial ca, plasmacytoid variant
High grade colorectal (rarely)
Gleason 5 prostate ca (also rarely)
Others
https://t.co/GTilCMwzOD
@commonsense_md@Jkylebass@POTUS@SecRubio@SDNYnews@SecScottBessent Recent grad. AMGs (US MD/DO) have a massive advantage over IMGs/FMGs in terms of residency selection; the barriers for FMGs to successfully practice in US are massive. However, foreign medical schools are much less costly. Would you take 500k in debt and uncertainty to be an AMG?
@awealthofcs@D8vidSmith I think using a VC exit strategy allows for sensible sizing.
Market cycle - “round”
Multiples (exit vs invested) - 10-40x (depends on risk tolerance). Aggregated, so actual appreciation might exceed that
Tail/residual - your rough estimate of store of value / global assets
@olsonplanner Traditionally path has had to do a fellowship to find jobs - however that is changing due to the job market and retirement cliff.
Nevertheless it may make sense for compensation (derm/hemepath), work life balance (molpath positions are largely hybrid/remote), or other reasons
@olsonplanner 3. Benefits - benefits for insurance etc can make the difference, especially if the spouse is in some high-paying PP/1099 job or small business.
@olsonplanner 2. Workload/hours - anecdotally, it is more chill. Some use this opportunity to supplement with locums/consulting work which juices up the returns.